Vikramjit Chhokar, MD
Cardiovascular Disease · Columbus, GANPI 1932101904
Payments from drug & device makers
Across 622 payments — averaging $28.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Medtronic$2K
- Edwards Lifesciences$2K
- Boston Scientific$1K
- Johnson & Johnson$1K
- Novartis$918
- plus $6K from 34 others
What the payments were for
- Travel & lodging$4,27924%
- Food & beverage$13,61076%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 131 | $4,517 |
| Medtronic(2 entities) | 21 | $2,127 |
| Edwards Lifesciences | 21 | $2,090 |
| Boston Scientific | 63 | $1,195 |
| Johnson & Johnson | 88 | $1,065 |
| Novartis | 57 | $918 |
| Pfizer | 51 | $836 |
| E.r. Squibb & Sons, L.L.C. | 41 | $682 |
| Novo Nordisk | 24 | $575 |
| Abiomed | 5 | $558 |
| Amgen | 28 | $553 |
| Kestra Medical Technology Services, Inc. | 1 | $383 |
| Shockwave Medical, Inc | 3 | $341 |
| Esperion Therapeutics, Inc. | 19 | $302 |
| AstraZeneca | 12 | $246 |
| Cvrx, Inc. | 2 | $188 |
| Merck | 11 | $186 |
| Irhythm Technologies, Inc. | 3 | $161 |
| Atricure, Inc. | 1 | $126 |
| Boehringer Ingelheim | 6 | $119 |
| Lantheus Medical Imaging, Inc. | 2 | $109 |
| Biotronik Inc. | 1 | $89 |
| Sanofi-aventis U.S. LLC | 5 | $82 |
| Inspire Medical Systems, Inc. | 2 | $53 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $52 |
| Alnylam Pharmaceuticals Inc. | 3 | $46 |
| Daiichi Sankyo Inc. | 2 | $45 |
| Gilead | 3 | $42 |
| Lundbeck LLC | 1 | $23 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $22 |
| Innovation Technologies Inc | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $18 |
| Vital Connect, Inc | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Angiodynamics, Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Elutia, Inc. | 1 | $14 |
| Cardiva Medical, Inc. | 1 | $12 |
| Penumbra, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$1,710
- Micra$1,052
- Edwards SAPIEN 3 Transcatheter Heart Valve$830
- Impella$516
- SAPIEN 3 Ultra RESILIA$406
- Assure WCD$383
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$315
- CARDIOMEMS$273
- MitraClip System$251
- AZURE XT DR MRI SURESCAN$174
- Barostim Neo System$160
- Resolute$155
- AMPLATZER Occluders$132
- Repatha$129
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$126
- ZIO XT Patch$123
- Unify Assura CRT Defibrillator$123
- ASSURITY$112
- GENERAL - THERAPIES$110
- CAMZYOS$110
How this compares
$17,891 in reported general payments places this provider in the 85th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 413 | $401,904 |
| XareltoRivaroxaban | 175 | $200,115 |
| EntrestoSacubitril/Valsartan | 118 | $125,265 |
| JardianceEmpagliflozin | 60 | $85,706 |
| FarxigaDapagliflozin Propanediol | 38 | $44,798 |
| WegovySemaglutide | 11 | $14,251 |
| Repatha SureclickEvolocumab | 11 | $11,617 |
| Praluent PenAlirocumab | 13 | $9,181 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 20 | $8,205 |
| Carvedilol | 782 | $6,589 |
| Ranolazine ErRanolazine | 61 | $6,179 |
| Metoprolol Succinate | 483 | $6,174 |
| Amiodarone Hcl | 79 | $4,537 |
| Spironolactone | 497 | $4,269 |
| LivaloPitavastatin Calcium | 11 | $4,198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $836 | $401,904413 claims |
| Johnson & JohnsonXarelto | $1,065 | $200,115175 claims |
| NovartisEntresto | $918 | $125,265118 claims |
| Boehringer IngelheimJardiance | $119 | $85,70660 claims |
| AstraZenecaFarxiga | $246 | $44,79838 claims |
| Novo NordiskWegovy | $575 | $14,25111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Columbus
- Hunter ChampionColumbus$1.5M
- Alonzo JonesColumbus$414K
- Hiren ShahColumbus$166K
- Narendra SinghJohns Creek$5.4M
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Naresh ParikhNorcross$2.8M
- Nicolas ChronosEatonton$2.4M
- Bobby KhanAtlanta$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.